Digital Therapeutics Companies Are Navigating a Complex Operating Environment
Prescription digital therapeutics — software-based treatments prescribed by clinicians and cleared by the FDA — represent one of the most commercially complex categories in health technology. Unlike traditional SaaS products, DTx companies must build and maintain relationships with prescribing physicians, support patient onboarding and adherence, navigate insurance coverage and prior authorization processes, and demonstrate clinical outcomes data that justifies reimbursement.
The global digital therapeutics market was valued at $6.4 billion in 2023 and is projected to grow at a compound annual rate of 20.1% through 2028, according to MarketsandMarkets. That growth is attracting capital but also raising the operational bar — companies that can't execute across prescriber development, patient support, and reimbursement simultaneously will struggle to reach commercial sustainability.
Virtual assistants are emerging as a cost-effective way to build that operational capacity.
Three Operational Challenges Unique to DTx Companies
Building prescriber networks. Unlike hospital enterprise sales, DTx prescriber development happens at the individual physician and practice level. A DTx company targeting substance use disorder treatment or insomnia might need to build relationships with thousands of primary care physicians, psychiatrists, or sleep medicine specialists across the country. That requires outreach, follow-up, educational material distribution, and CRM maintenance at a scale that far exceeds what small commercial teams can manage alone.
Onboarding patients and maintaining adherence. When a physician prescribes a DTx product, the patient must download the app, complete onboarding, and begin an engagement protocol that may last weeks or months. Each step in that process is a potential dropout point. Consistent outreach — welcome calls, adherence check-ins, troubleshooting support — is essential to outcomes data and, by extension, to the payer value proposition.
Navigating reimbursement. Coverage for prescription digital therapeutics varies widely by payer and geography. Prior authorization requirements, appeals, and patient assistance program administration create substantial administrative workload that falls on teams that are often too small to handle it without support.
How VAs Are Being Deployed Across the DTx Value Chain
Virtual assistants working in DTx environments are handling tasks across multiple functional areas:
- Prescriber outreach coordination: scheduling detail calls, sending educational materials, tracking follow-up cadences in Salesforce or similar CRM tools
- Medical office support: helping prescribers' staff understand prior authorization requirements, formulary status, and patient assistance pathways
- Patient welcome and onboarding calls: walking newly prescribed patients through app download, account setup, and the first week of the program
- Adherence monitoring outreach: contacting patients who have gone inactive in the platform and offering support before they formally disenroll
- Prior authorization documentation: gathering clinical notes and diagnosis codes from prescribers to support reimbursement submissions
- Appeals coordination: preparing appeal packages for denied prior authorizations under direction from reimbursement teams
- Conference and speaker program logistics: managing advisory board scheduling, speaker bureau documentation, and continuing medical education event coordination
- Executive and administrative support: calendar management, travel coordination, and board presentation preparation
These functions collectively represent the commercial and operational engine of a DTx company — and most of them are well-suited to experienced VA support.
The Economics of VA-Supported DTx Operations
The alternative to VA support at most DTx companies is a combination of overextended field representatives, contract workers, and deferred work. A dedicated DTx field sales representative costs $120,000 to $160,000 annually with benefits and expenses in major markets. Patient success managers run $65,000 to $90,000. Reimbursement specialists command $70,000 to $95,000.
Virtual assistants capable of supporting these functions typically cost $12 to $30 per hour, and most DTx companies can achieve the required support coverage with 20 to 40 hours per week across multiple functions. The annual cost difference is significant — often representing more than $50,000 per function supported.
Dr. Ana Ruiz, a DTx commercialization consultant cited in Digital Therapeutics Alliance publications in 2024, noted that "the companies that are burning through their Series B cash too fast are almost always the ones that hired full-time for every function. The smarter operators built a flexible support infrastructure and held the full-time headcount for the roles that genuinely require it."
HIPAA Considerations for DTx VA Programs
Patient data handled in DTx operations — prescription records, adherence data, prior authorization documentation — is protected health information. Virtual assistants working in DTx environments must operate under business associate agreements, within HIPAA-compliant communication tools, and with training appropriate to the sensitivity of the information they handle.
Reputable DTx-focused VA providers build these compliance requirements into their standard onboarding and operating protocols, reducing compliance risk for the companies they serve.
The Path to Sustainable Scale
Digital therapeutics companies that build scalable prescriber development, patient engagement, and reimbursement support infrastructure early are positioned to demonstrate the outcomes data that drives payer coverage and commercial sustainability. Virtual assistants are a cost-effective way to build that infrastructure without the fixed-cost risk of full-time hiring at every function.
Stealth Agents offers virtual assistants with experience supporting healthcare commercial operations, prescriber outreach programs, and patient engagement functions. Their trained professionals help DTx companies build the operational foundation required for sustainable commercial growth.
Looking Ahead
As the DTx market matures and payers develop more consistent reimbursement frameworks, the companies that win will be the ones with the strongest commercial execution. Virtual assistants are a practical, scalable tool for building that execution capacity — and the companies investing in them now are building durable operational advantages.
Sources
- MarketsandMarkets, Digital Therapeutics Market Report, 2023
- Digital Therapeutics Alliance, Industry Standards and Operating Model Analysis, 2024
- FDA, Software as a Medical Device Guidance, 2023
- IQVIA Institute for Human Data Science, "Digital Health Trends," 2023